The Future of Healthcare: The Potential and Challenges of Virtual Wards

By Staff Writer

November 14, 2023

Embracing the Potential and Challenges of Virtual Wards

The National Institute for Health and Care Excellence (NICE) has recently recommended the exploration of virtual wards in healthcare. Virtual care is not a new concept. Recent health crises, like the COVID-19 pandemic, have propelled it into the spotlight. Virtual care, including telehealth and remote patient monitoring, has shown great promise in improving access to care, especially for those in remote or underserved areas. For example, early warning scores, such as NEWS2 and CRB65, are transforming the way we assess patients with suspected Acute Respiratory Infections (ARIs). These scores offer a promising avenue for clinical decision-making, especially in remote settings like call centres or primary care. They can be instrumental in determining care pathways, such as whether to send patients home, to ARI virtual wards, or to same day emergency care.

 

The Future of Remote Contact with NHS Services

Remote contact with National Health Service (NHS) services is gaining momentum. The guideline committee has made recommendations based on their expertise and experience, despite the fact that there is a lack of evidence on the use of remote assessments for those who have a suspicion that they have ARI. They are of the opinion that remote evaluations can be a beneficial tool for identifying persons who do not have major illnesses. However, they believe that an in-person assessment is essential for people who do have severe diseases.

The committee has also emphasised the significance of accessibility. Recognising that not everyone has equal access to or the capacity to use digital technology. However, they have emphasised the value of accessibility nonetheless. As a result, they have suggested that alternatives should be provided whenever they are required, and that the NHS has a responsibility to give reasonable adjustments to patients who have requirements in this regard.

As a result of the committee’s recommendations, antimicrobial stewardship is expected to be improved. This will lead to the beginning of a new era in healthcare. This will be accomplished by reducing the amount of antimicrobials that are prescribed without an in-person assessment.

Reference url

Recent Posts

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

ivonescimab clinical trials
    

Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaboration with Pfizer

🚀 Exciting news in the fight against cancer!

Summit Therapeutics has announced a groundbreaking collaboration with Pfizer to launch clinical trials for ivonescimab, an innovative PD-1/VEGF bispecific antibody. This partnership aims to evaluate the safety and effectiveness of ivonescimab in combination with Pfizer’s antibody drug conjugates across various solid tumors, including non-small cell lung cancer. 🌟

To learn more about this promising development and its potential impact on oncology treatment, dive into the full article!

#SyenzaNews #oncology #clinicaltrials #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.